Takeda will begin production of the Nuvaxovid vaccine soon

Takeda received approval from the Japanese Ministry of Health to manufacture and sell the Covid-19 vaccine Nuvaxovid. Novavax had previously licensed and transferred its production technology so that Takeda could develop and produce the vaccine at its Hikari facility. The company will begin producing the doses purchased by the Japanese government in the near future.